A federal judge has put a hold on any further proceedings in the massive, years-long nationwide legal action against Abbvie and other makers of so-called testosterone replacement therapy drugs, saying he wants to give both sides time to complete a potential settlement drug to permanently end the litigation.
Recent News About Paul, Weiss, Rifkind, wharton & Garrison LLP View More
Chase to pay $19M to settle black financial advisors' suit alleging denied opportunities; lawyers to claim $5.5M
JP Morgan Chase Bank has agreed to pay more than $19.5 million to settle a class action suit brought in Chicago federal court by several of its employees, who alleged the banking giant assigned its black and African-American financial advisors to less profitable locations and denied them other opportunities to get ahead, because of their race.
North Chicago-based drug company AbbVie is urging a federal judge to trash a verdict ordering it to cough up $140 million, because its testosterone therapy drug AndroGel contributed to a man's heart attack, contending it has no liability because AndroGel was approved by the FDA.